Given their widespread use and overall safety profile, DPP-4 inhibitors remain a first-line or second-line treatment for many Japanese individuals with type 2 diabetes, though careful monitoring is warranted in specific high-risk populations. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.